Allarity Therapeutics Stock Today

ALLR Stock  USD 0.16  0.01  5.88%   


0 of 100

Very Weak

Odds Of Distress

Over 85

Very High
Allarity Therapeutics is selling at 0.16 as of the 23rd of July 2024; that is 5.88 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.14. Allarity Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Allarity Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of January 2023 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
21st of December 2021
Health Care
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts. The company has 25.59 M outstanding shares of which 1.72 M shares are presently shorted by private and institutional investors with about 0.35 trading days to cover. More on Allarity Therapeutics

Moving together with Allarity Stock

  0.81EQ EquilliumPairCorr

Moving against Allarity Stock

  0.93HALO Halozyme TherapeuticsPairCorr
  0.88LLY Eli LillyPairCorr
  0.88INCY Incyte Earnings Call This WeekPairCorr
  0.76PFE Pfizer Inc Earnings Call This WeekPairCorr
  0.36DMAC DiaMedica TherapeuticsPairCorr

Allarity Stock Highlights

CEO, FounderThomas Jensen
Old NameAllarity Therapeutics A/S
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0030.0034
Fairly Down
Slightly volatile
Total Current Liabilities11.7 M14.2 M
Significantly Down
Pretty Stable
Non Current Liabilities Total423.7 K446 K
Notably Down
Slightly volatile
Total Assets22.6 M11.9 M
Way Up
Slightly volatile
Total Current Assets1.9 MM
Notably Down
Pretty Stable
Debt Levels
Allarity Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Allarity Therapeutics' financial leverage. It provides some insight into what part of Allarity Therapeutics' total assets is financed by creditors.
Allarity Therapeutics currently holds 1.3 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Allarity Therapeutics has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Allarity Therapeutics' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

Allarity Therapeutics (ALLR) is traded on NASDAQ Exchange in USA. It is located in 24 School Street, Boston, MA, United States, 02108 and employs 5 people. Allarity Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.2 M. Allarity Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.59 M outstanding shares of which 1.72 M shares are presently shorted by private and institutional investors with about 0.35 trading days to cover. Allarity Therapeutics currently holds about 7.73 M in cash with (12.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Allarity Therapeutics Probability Of Bankruptcy

Allarity Stock Institutional Holders

InstituionRecorded OnShares
Tower Research Capital Llc2023-12-31
5.5 K
Wells Fargo & Co2023-12-31
Sabby Management Llc2023-12-31
Armistice Capital, Llc2023-12-31
Virtu Financial Llc2024-03-31
Two Sigma Securities, Llc2024-03-31
View Allarity Therapeutics Diagnostics

Allarity Therapeutics Historical Income Statement

At this time, Allarity Therapeutics' Interest Expense is relatively stable compared to the past year. As of 07/23/2024, Interest Income is likely to grow to about 36.2 K, while Net Loss is likely to drop (25.4 M). View More Fundamentals

Allarity Stock Against Markets

Allarity Therapeutics Corporate Management

Professor MDCoFounderProfile
Joan BrownInterim ReportingProfile
James JDChief CEOProfile
Steen KnudsenFounder OfficerProfile
Annie RasmussenChief OperationsProfile
Claus PedersenChief OfficerProfile
MD DrScChief OfficerProfile

Already Invested in Allarity Therapeutics?

The danger of trading Allarity Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allarity Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allarity Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allarity Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Allarity Stock Analysis

When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.